For the study, the researchers gave the study participants an experimental anti-amyloid drug. They found that 22 participants ...

Alzheimer's disease is usually associated with old age. But around 5%-10% of all Alzheimer's cases occur in people under the age of 65. Early-onset ...

A bioengineer highlights the potential of low-intensity ultrasound for multiple uses, from enhanced drug delivery to the ...

A study published in Brain Communications revealed new insights into early detection of Alzheimer’s disease. Researchers have ...

“The benefits of Kisunla were not large enough to outweigh the risks of potentially fatal events,” the agency said, citing ...

Research shows experimental anti-amyloid drug reduced cognitive symptom risk by 50% in people with rare genetic mutations ...

Washington University School of Medicine led a study evaluating long-term gantenerumab treatment in individuals with dominantly inherited Alzheimer's disease (DIAD). Gantenerumab was associated with ...

The European Medicines Agency has rejected Lilly’s Alzheimer’s drug Kisunla for a license, saying its benefits don’t outweigh the risk of brain swelling or bleeding. The treatment for early ...

A clinical trial involving individuals genetically predisposed to develop early-onset Alzheimer’s disease suggests that ...

A study examining the long-term effects of anti-amyloid therapy gantenerumab suggests that full amyloid plaque removal may help reduce Alzheimer’s symptoms in individuals at risk for dominantly ...

The brain's immune cells removed plaques and helped restore a healthier environment in the brains of immunized patients. For over 30 years, scientists have focused on treating Alzheimer’s disease by ...